India: Dr Reddy’s gains foothold in US women’s health with Mayne’s product portfolio

Dr Reddy’s Laboratories is to acquire the US generic prescription product portfolio of Australia based Mayne Pharma Group, an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals. The firm will acquire the portfolio for an upfront payment of approximately US$90m in cash, contingent payments of up to US$15m, consideration towards inventory and…

You must be a HMI Subscriber to view this content.

Subscribe Now »